NATIONAL INSTITUTES OF HEALTH

Cabometyx (cabozantinib) showed significant reduction in disease progression or death risk in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs) compared to placebo, according to final data from the CABINET Phase III trial. Ipsen has submitted an extension of indication Marketing Authorization to the European Medicines Agency. The data were presented at ESMO 2024 and published in the New England Journal of Medicine.

Final CABINET Phase III trial data showed Cabometyx significantly reduced disease progression or death risk in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs) compared to placebo, presented at ESMO 2024 and published in NEJM. Ipsen has submitted an extension of indication Marketing Authorization to the EMA, addressing limited treatment options for advanced NETs.

Research focuses on precision treatment of tumors, particularly in radiation oncology, aiming to personalize radiation therapy doses using biomarkers like the NAR score and GARD model. These tools predict neoadjuvant radiotherapy efficacy and survival outcomes, suggesting individualized doses could improve treatment outcomes for locally advanced rectal cancer (LARC) patients.

A new 10-minute AI-powered blood test, IntelliSep, may soon be available in hospitals to diagnose sepsis, potentially saving lives by providing rapid and reliable detection.

SPRINT and ACCORD-BP trials pooled for post-hoc analysis; SPRINT tested intensive BP control (SBP < 120 mmHg) vs. standard (SBP < 140 mmHg) in high CVD risk non-DM participants, while ACCORD-BP used a 2x2 factorial design in high CVD risk DM participants. Outcome of interest was stroke-free survival (SFS), analyzed using Kaplan-Meier curves and Cox proportional hazards models. Data available at https://biolincc.nhlbi.nih.gov.

FDA approval of venetoclax inspired a scientist's passion for bridging research and medicine at WEHI. The collaborative atmosphere and diverse knowledge inspire continuous innovation. The scientist's motivation stems from impacting patient lives through medical and scientific advancements. Immunology's complexity and potential excite, while experiences at NIH and pioneering degrees highlight career highlights and challenges. Collaboration is key, and outside the lab, the scientist enjoys Melbourne's food scene and travel.

About half of metastatic melanoma patients treated with immune checkpoint inhibitors survive cancer-free for 10+ years, per a 10-year follow-up study from Weill Cornell Medicine and Dana-Farber Cancer Institute. The CheckMate 067 trial, involving 945 patients, showed nivolumab and ipilimumab combination significantly improved outcomes, with no new safety concerns. Median survival increased from 6.5 months to over 6 years, and patients free from cancer progression at 3 years likely remain disease-free at 10 years.